Silo Pharma Expands into AI Agents with Qwikagents Acquisition — Silo Pharma, Inc.

Event summary

Silo Pharma acquires Qwikagents.ai, an AI platform for autonomous agents, to enter the multi-billion-dollar AI agent market.
The AI agent market is projected to reach $47–$53 billion by 2030, with annual growth rates of 43% to 50%.
Silo Pharma forms a dedicated subsidiary to manage the Qwikagents asset and future AI infrastructure technologies.
The company remains committed to advancing its PTSD program into Phase 1 clinical trials.

The big picture

Silo Pharma's acquisition of Qwikagents.ai marks a strategic pivot into the high-growth AI agent market, complementing its existing biopharmaceutical and cryptocurrency operations. The move positions the company to capitalize on the rapidly expanding AI infrastructure sector while maintaining its focus on therapeutic advancements. The AI agent market's projected growth and Silo Pharma's ability to integrate this new business line will be critical factors in its long-term success.

What we're watching

Revenue Diversification: How Silo Pharma will balance its biopharmaceutical focus with the new AI infrastructure business.
Market Growth: Whether the AI agent market will meet projected growth rates of 43% to 50% annually.
Regulatory Approval: The timeline for FDA approval of Silo Pharma's PTSD program and its impact on the company's strategic priorities.